Mechanosensitive Channel Piezo1 in Calcium Dynamics: Structure, Function, and Emerging Therapeutic Strategies

Yong-wang Li^1,2*Yu Liu^1,2Yu-Qiu Xu¹Yu-Yin Long¹Hui Xiao¹Yu-Ying Ma¹

• ¹The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
• ²Department of Anesthesiology, The Third People's Hospital of Longgang, Clinical Institute of Shantou University Medical College（The Third People's Hospital of Longgang District Shenzhen）, Shenzhen, China

Piezo1, a trimeric mechanosensitive cation channel discovered in 2010 and recognized with the 2021 Nobel Prize for its seminal role in mechanotransduction, has emerged as a key transducer of mechanical forces into calcium ions (Ca²⁺) signaling. Its distinctive propeller-like structure confers high mechanosensitivity, enabling rapid and graded Ca²⁺ influx under diverse mechanical stimuli such as shear stress, stretch, or compression. This Ca²⁺ entry establishes localized nanodomains and amplifies signals via Ca²⁺-induced Ca²⁺ release, thereby activating a spectrum of downstream effectors including CaMKII, NFAT, and YAP/TAZ. Through these pathways, Piezo1 orchestrates critical physiological processes including vascular tone, skeletal remodeling, immune responses, neural plasticity, and organ development. Conversely, its dysregulation drives numerous pathologies, ranging from hypertension and atherosclerosis to neurodegeneration, fibrosis, osteoarthritis, and cancer. Advances in pharmacological modulators (e.g., Yoda1, GsMTx4), gene-editing, and nanomedicine underscore promising therapeutic opportunities, though challenges persist in tissue specificity, off-target effects, and nonlinear Ca²⁺ dynamics. This review synthesizes current knowledge on Piezo1-mediated Ca²⁺ signaling, delineates its dual roles in physiology and disease, and evaluates emerging therapeutic strategies. Future integration of structural biology, systems mechanobiology, and artificial intelligence is poised to enable precision targeting of Piezo1 in clinical practice.